|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||327.88 - 334.00|
|52-week range||299.01 - 430.00|
|Beta (5Y monthly)||0.26|
|PE ratio (TTM)||17.48|
|Forward dividend & yield||9.97 (3.05%)|
|Ex-dividend date||17 Mar 2022|
|1y target est||423.65|
Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.
Roche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails. Sanofi's (SNY) Enjaymo to treat a rare form of anemia gets approval in Europe.
Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.